In this issue of Med, Bian et al. present a post-hoc analysis of the phase 3 CHART trial investigating rezvilutamide in the metastatic hormone-sensitive prostate cancer setting.1 They show that ...

To address the concern that polygenic hazard scores for prostate cancer (PCa) might not distinguish between indolent and aggressive disease, we performed case-only analyses using a 601-variant ...

Over the past 20 years, early diagnosis of prostate cancer has become increasingly prevalent due to the promotion of prostate-specific antigens, and its treatment has become a focal point. However, ...

Sarcomatoid urothelial carcinoma (SUC) is a rare histologic subtype with poor prognosis. While there is known intra-tumoral heterogeneity between individual SUC tumors, the relationship between ...

Sarcomatoid differentiation is an example of epithelial-mesenchymal transition and is present in 5% of localized and 20% of metastatic RCC. Although the impacts of pathological characteristics and the ...

To quantify physicians' preferences for adjuvant renal cell carcinoma (RCC) treatments. A discrete-choice experiment was administered online to board-certified/eligible physicians. Physicians chose ...

To examine the risk of progression and time to progression from penile intraepithelial neoplasia (PeIN) to invasive penile cancer in patients treated for PeIN with either surgery, laser ablation or ...

Traditional PSA-based screening for prostate cancer (PCa) is challenged by an unfavorable benefit-to-harm ratio from underdiagnosis of clinically significant cancers, overdiagnosis of indolent cancers ...

Penile cancer is a rare neoplasm with heterogeneous prevalence influenced by risk factors such as smoking, poor hygiene and human papillomavirus (HPV) infection. Southern Africa, South America and ...

Patients with Prostate Imaging Reporting and Data System (PI-RADS) 5 lesions are at a high risk of clinically significant prostate cancer (PCa), extracapsular extension, and biochemical recurrence ...

Research has helped to better understand renal cell carcinoma and enhance management of patients with locally advanced and metastatic disease. More recently, artificial intelligence has emerged as a ...

Amplification of the androgen receptor (AR) locus is the most frequent alteration in metastatic castration-resistant prostate cancer (CRPC). Recently, it was discovered that an enhancer of the AR is ...